TIGERMED: 2025 FIRST QUARTERLY REPORT

TIGERMED announced its performance for the first quarter of 2025, achieving revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%; net profit attributable to shareholders was 0.165 billion yuan, a year-on-year decrease of 29.61%; basic EPS was 0.19 yuan. Cash flow from operating activities (CFO) was a net amount of 0.198 billion yuan, a year-on-year increase of 37.26%.In the first quarter of 2025, the company performed well in new orders, with a net increase in contract amount exceeding 2 billion yuan, a year-on-year increase of 20%, with domestic customers showing a significant recovery in new orders. During the period, interest of 21.828 million yuan from purchasing large-denomination certificates of deposit was reclassified as investment income, while interest income from large-denomination...Show More

TIGERMED announced its performance for the first quarter of 2025, achieving revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%; net profit attributable to shareholders was 0.165 billion yuan, a year-on-year decrease of 29.61%; basic EPS was 0.19 yuan. Cash flow from operating activities (CFO) was a net amount of 0.198 billion yuan, a year-on-year increase of 37.26%.In the first quarter of 2025, the company performed well in new orders, with a net increase in contract amount exceeding 2 billion yuan, a year-on-year increase of 20%, with domestic customers showing a significant recovery in new orders. During the period, interest of 21.828 million yuan from purchasing large-denomination certificates of deposit was reclassified as investment income, while interest income from large-denomination certificates of deposit last year was recorded as financial expenses at 16.466 million yuan, affecting a total of 38.294 million yuan.During the reporting period, the company actively promoted the development of digital and Asia Vets technology, and it is expected to continue investing in the subsequent period. At the same time, the company implemented a share buyback, and as of March 31, 2025, the number of shares held in the dedicated repurchase securities account was 9.8063 million shares, accounting for 1.13%.